Cypherpunk Technologies Inc（CYPH）の株式分析CYPHCypherpunk Technologies Inc

Cypherpunk Technologies Inc., formerly Leap Therapeutics, Inc., is engaged in developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The Company focuses on the development of sirexatamab and FL-501 to treat patients with cancer. Zcash is a privacy-preserving blockchains, launched as a fork of Bitcoin with advanced cryptography that enables selective transparency. Zcash has introduced privacy technology through the use of zero-knowledge proofs (zk-SNARKs), allowing transactions to be verified without revealing sender, receiver, or amount. FL-501 is a potential class antibody designed to neutralize GDF-15 and prevent the binding to its receptor. sirexatamab (DKN-01), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. Sirexatamab is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. It operates in the Healthcare sector.

Cypherpunk Technologies Inc is a good buy right now, primarily due to its recent price increase of 20.42% over the last five days and a significant 189.54% increase over the last 20 days. Additionally, the RSI is currently at 72.781, indicating strong momentum. However, the company reported a net income loss of $77,166,000 in Q1 2026, which poses a risk to its financial stability.